• Use of stem cells to treat ischemic cardiovascular disease. 
• Clinical studies evaluating the effect of stem cells in the treatment of ischemic cardiomyopathies. 
• Cellular and molecular mechanisms of cell therapy. 
• Ex vivo organ perfusion: lung, liver, kidney and heart. 
• Lung transplantation. 
• Preconditioning of stem cells and organs to enhance their function. 
• Development of molecules to enhance the therapeutic potential of stem cells. 
• Coronary bypass surgery and complex cases. 
• Small and large animal pre-clinical experimental models reproducing various human pathologies.

Biography

Dr. Noiseux is a cardiac surgeon since 2002, full professor (tenured) Université de Montréal, QC, Canada, director of research in cardiovascular surgery (CHUM). Training for both basic and clinical sciences: BSc in Biochemistry, MSc in Molecular biology, cardiac surgeryn (FRCSC), and a research fellowship at Harvard Medical School in regenerative medicine and cellular therapy. Commissioned Colonel by the Governor of the Commonwealth of Kentucky USA in 2018 for outstanding personal and professional achievements. 

He is leading a translational research program in regenerative medicine and clinical trials addressing key questions in cardiology and transplantation. PI/co-PI on investigator-initiated projects, but also with major role/involvement and steering committees in international clinical trials leading to publications in high-impact journals and lectures worldwide. 

He is the director of cardiovascular medicine at the CHUM. He initiated COMPARE-AMI and IMPACT-CABG trials combining 80n patients treated with intracardiac transplantation of CD133+n stem cells to treat heart failure: first Canadian experience and a major milestone in the field. He possesses valuable and unique surgical skills in preclinical experimental models mimicking a variety of human diseases in both small and large animals. He set up various platforms for in vitro, ex vivo and in vivo experiments to study animals up to humans, at the cellular or whole organ levels and organ perfusion systems for the heart, the lungs and liver. 

Performing the lung transplantations at the CHUM, he initiated in 2014 with Dr. Pasquale Ferraro (chair in lung transplant) the program of ex-vivo lung perfusion both clinically and in large animals with more than 130 procedures so far. 

Dr. Noiseux has been very successful in developing cutting edge translational research for innovative therapies to reduce ischemia-reperfusion injury to increase the number and quality of organs for transplantation, he is the co-founder and CMO of Targa biomedical.